

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number  
**WO 2004/054565 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/197**,  
A61P 1/00, 25/18, 29/00, 43/00, 5/00

David, Juergen [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US).

(21) International Application Number:  
PCT/IB2003/005684

(74) Agents: LUMB, J., Trevor et al.; c/o David J. Wood, Pfizer Global Research and Development, UK Patent Department, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(22) International Filing Date: 3 December 2003 (03.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/433,491 13 December 2002 (13.12.2002) US  
60/483,482 27 June 2003 (27.06.2003) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*):  
**WARNER-LAMBERT COMPANY LLC** [US/US];  
201 Tabor Road, Morris Plains, NJ 07950 (US).

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **TAYLOR, Charles, Price, Jr.** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **THORPE, Andrew, John** [GB/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (GB). **WANG, Fong** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **WUSTROW,**

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PREGABALIN AND DERIVATES THEREOF FOR THE TREATMENT OF FIBROMYALGIA AND OTHER RELATED DISORDERS



(57) Abstract: The invention relates to a method of treating fibromyalgia and other disorders in a mammal by administering a compound compound of Formula R<sub>1</sub> is straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms; R<sub>2</sub> is hydrogen or methyl; and R<sub>3</sub> is hydrogen, methyl, or carboxyl, or a pharmaceutically acceptable salt thereof.

WO 2004/054565 A1

USSN 10/731,605 FILED December 9, 2003  
Docket No. PC25026A

-1-

## PREGABALIN AND DERIVATIVES THEREOF FOR THE TREATMENT OF FIBROMYALGIA AND OTHER RELATED DISORDERS

This invention relates to methods of treating various central nervous system and other disorders by administering certain compounds that exhibit activity as calcium channel  $\alpha 2\delta$  ligands ("α2δ ligands" or "alpha2delta ligands"). Such compounds have affinity for the α2δ subunit of a calcium channel. Such compounds have also been referred to in the literature as gamma-aminobutyric acid (GABA) analogs.

Background Of The Invention

Several alpha2delta ligands are known. Gabapentin, a cyclic alpha2delta ligand, is now commercially available (Neurontin®, Warner-Lambert Company) and extensively used clinically for treatment of epilepsy and neuropathic pain. Such cyclic alpha2delta ligands are described in US Patent No. 4,024,175, which issued on May 17, 1977, and US Patent No. 4,087,544, which issued on May 2, 1978. Other series of alpha2delta ligands are described in US Patent No. 5,563,175, which issued on October 8, 1996, US Patent No. 6,316,638, which issued on November 13, 2001, US Provisional Patent Application 60/353,632, which was filed on January 31, 2002, US Provisional Patent Application 60/248,630, which was filed on November 2, 2002, US Provisional Patent Application 60/421,868, which was filed on October 28, 2002, US Provisional Patent Application 60/421,867, which was filed on October 28, 2002, US Provisional Patent Application 60/413,856, which was filed on September 25, 2002, US Provisional Patent Application 60/411,493, which was filed on September 16, 2002, US Provisional Patent Application 60/421,866, which was filed on October 28, 2002, US Provisional Patent Application 60/441,825, which was filed on January 22, 2003, US Provisional Patent Application 60/452,871, which was filed on March 7, 2003, European Patent Application EP 1112253, which was published on July 4, 2001, PCT Patent Application WO 99/08671, which was published on February 25, 1999, and PCT Patent Application WO 99/61424, which


-2-

was published on December 2, 1999. These patents and applications are incorporated herein by reference in their entireties.

Additional uses for alpha2delta ligands, including compounds of the formula I, which are defined below, are referred to in US Provisional Patent Application 60/433,491, which was filed on December 13, 2002. This application is incorporated herein by reference in its entirety.

### Summary Of The Invention

This invention relates to a method of treating fibromyalgia in a mammal, preferably a human, comprising administering to a mammal in need of such treatment a therapeutically effective amount of an alpha2delta ligand of the formula I



or a pharmaceutically acceptable salt thereof, wherein:

R<sub>1</sub> is a straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

R<sub>2</sub> is hydrogen or methyl; and

R<sub>3</sub> is hydrogen, methyl, or carboxyl.

Fibromyalgia (FM) is a chronic syndrome characterized mainly by widespread pain, unrefreshing sleep, disturbed mood, and fatigue. Other syndromes commonly comorbid with fibromyalgia include irritable bowel syndrome, migraine headaches, depression and insomnia, among others. Success of treating fibromyalgia with a single pharmacological agent has been characterized as modest and results of clinical trials have been characterized as disappointing. It is believed that based on current understanding of the mechanisms and pathways involved in fibromyalgia,

-3-

multiple agents will be required, aimed at the major symptoms of pain, disturbed sleep, mood disturbances, and fatigue. Fibromyalgia patients are often sensitive to side effects of medications, a characteristic perhaps related to the pathophysiology of this disorder (Barkhuizen A, Rational and Targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin N Am 2002; 28: 261-290; Leventhal LJ. Management of fibromyalgia. Ann Intern Med 1999;131:850-8).

While fibromyalgia is a complex disorder with multiple facets, this complexity can be well assessed (Yunus MB, A comprehensive medical evaluation of patients with fibromyalgia syndrome, Rheum Dis N Am 2002; 28:201-217). The diagnosis of FM is usually based on the 1990 recommendations of the American College of Rheumatology classification criteria (Bennett RM, The rational management of fibromyalgia patients. Rheum Dis Clin N Am 2002; 28: 181-199; Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33:160-72). Evaluation, management, and pharmacological treatment of fibromyalgia have been reviewed (Barkhuizen A, Rational and Targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin N Am 2002; Buskila D, Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome. Current opinions in Rheumatology 2001; 13: 117-127; Leventhal LJ. Management of fibromyalgia. Ann Intern Med 1999;131:850-8; Bennett RM, The rational management of fibromyalgia patients. Rheum Dis Clin N Am 2002; 28: 181-199; Yunus MB, A comprehensive medical evaluation of patients with fibromyalgia syndrome, Rheum Dis N Am 2002; 28:201-217 ).

A more specific method of this invention relates to the above method of treating fibromyalgia wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia that is accompanied by one or more somatic symptoms selected from fatigue, headache, neck pain, back pain, limb pain, joint pain, abdominal pain, abdominal distention, gurgling, diarrhea

-4-

nervousness, and the symptoms associated with generalized anxiety disorder (*e.g.*, excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least six months, about a number of events and activities, difficulty controlling the worry, etc.) See Diagnostic and Statistical manual of Mental Disorders, Fourth Edition (DSM-IV),  
5 American Psychiatric Association, Washington, D.C., May 1194, pp. 435-436 and 445-469.

This invention also relates to a method of treating a disorder or condition selected from the group consisting of sleep disorders such as  
10 insomnia (*e.g.*, primary insomnia including psychophysiological and idiopathic insomnia, secondary insomnia including insomnia secondary to restless legs syndrome, Parkinson's disease or another chronic disorder, and transient insomnia), somnambulism, sleep deprivation, REM sleep disorders, sleep apnea, hypersomnia, parasomnias, sleep-wake cycle  
15 disorders, jet lag, narcolepsy, sleep disorders associated with shift work or irregular work schedules, deficient sleep quality due to a decrease in slow wave sleep caused by medications or other sources, and other sleep disorders in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the  
20 formula I, or a pharmaceutically acceptable salt thereof.

This invention also relates to a method of increasing slow wave sleep in a human subject comprising administering to a human subject in need of such treatment a therapeutically effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.

25 This invention also relates to a method of increasing growth hormone secretion in a human subject comprising administering to a human subject in need of such treatment a therapeutically effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.

This invention also relates to a method of increasing slow wave sleep  
30 in a human subject comprising administering to a human subject in need of such treatment:

(a) a compound of the formula I or a pharmaceutically acceptable salt thereof; and

-5-

(b) a human growth hormone or a human growth hormone secretagogue or a pharmaceutically acceptable salt thereof; wherein the amounts of the active agents "a" and "b" are chosen so as to render the combination effective in increasing slow wave sleep.

5 A more specific embodiment of this invention relates to the above method wherein the human growth hormone secretagogue that is employed is 2-amino-N-[2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazole[4,3-c]pyridin-5-yl)-1-benzyloxymethyl-2-oxo-ethyl]-2-methyl-propionamide.

10 This invention also relates to a method of increasing slow wave sleep in a human subject being treated with an active pharmaceutical agent that decreases slow wave sleep, such as morphine or another opioid analgesic agent or a benzodiazepine, comprising administering to a human subject in need of such treatment:

15 (a) a compound of the formula I or a pharmaceutically acceptable salt thereof; and

(b) a human growth hormone or a human growth hormone secretagogue or a pharmaceutically acceptable salt thereof; wherein the amounts of the active agents "a" and "b" are chosen so as to render the combination effective in increasing slow wave sleep.

20 A more specific embodiment of this invention relates to the above method wherein the human growth hormone secretagogue that is employed is 2-amino-N-[2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazole[4,3-c]pyridin-5-yl)-1-benzyloxymethyl-2-oxo-ethyl]-2-methyl-propionamide.

25 This invention also relates to a method of increasing slow wave sleep in a human subject being treated with an active pharmaceutical agent that decreases slow wave sleep, such as morphine or another opioid analgesic agent, comprising administering to such human subject an amount of a compound of the formula I, as defined above, or a pharmaceutically acceptable salt thereof, that is effective in increasing slow wave sleep.

30 This invention also relates to a method of treating irritable bowel syndrome in a mammal, preferably a human, comprising administering to a

-6-

human subject in need of such treatment a therapeutically effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

5 This invention also relates to a method of treating a disorder or condition selected from the group consisting of panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias (*e.g.*, specific animal phobias), social anxiety disorder, social phobia, obsessive-compulsive disorder (OCD), and stress disorders including post-traumatic stress disorder and acute stress disorder in a  
10 mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

A more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is post-traumatic  
15 stress disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is social phobia or social anxiety disorder.

Another more specific embodiment of this invention relates to the above method wherein the disorder or condition being treated is OCD.  
20

It will be appreciated that for the treatment of panic disorder, phobias, OCD and stress disorders, the compounds of formula I may be used in conjunction with other antidepressant or anti-anxiety agents. Suitable classes of anti-depressant agent include norepinephrine reuptake  
25 inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists,  $\alpha$ -adrenoreceptor antagonists and atypical antidepressants. Suitable norepinephrine  
30 reuptake inhibitors include tertiary amine tricyclics and secondary amine tricyclics. Suitable examples of tertiary amine tricyclics include amitriptyline, clomipramine, doxepin, imipramine and trimipramine, and

-7-

pharmaceutically acceptable salts thereof. Suitable examples of secondary amine tricyclics include amoxapine, desipramine, maprotiline, nortriptyline and protriptyline, and pharmaceutically acceptable salts thereof. Suitable selective serotonin reuptake inhibitors include fluoxetine, 5 fluvoxamine, paroxetine and sertraline, and pharmaceutically acceptable salts thereof. Suitable monoamine oxidase inhibitors include isocarboxazid, phenelzine, tranylcypromine and selegiline, and pharmaceutically acceptable salts thereof. Suitable reversible inhibitors of monoamine oxidase include moclobemide, and pharmaceutically acceptable salts thereof. Suitable serotonin and noradrenaline reuptake inhibitors of use in the present invention include venlafaxine, and pharmaceutically acceptable salts thereof. Suitable CRF antagonists include those compounds described in International Patent Application Nos. WO 94/13643, WO 94/13644, WO 94/13661, WO 94/13676 and WO 15 94/13677. Suitable atypical anti-depressants include bupropion, lithium, nefazodone, trazodone and viloxazine, and pharmaceutically acceptable salts thereof. Suitable classes of anti-anxiety agents include benzodiazepines and 5-HT<sub>1A</sub> agonists or antagonists, especially 5-HT<sub>1A</sub> partial agonists, and corticotropin releasing factor (CRF) antagonists. 20 Suitable benzodiazepines include alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam, and pharmaceutically acceptable salts thereof. Suitable 5-HT<sub>1A</sub> receptor agonists or antagonists include, in particular, the 5-HT<sub>1A</sub> receptor partial agonists buspirone, flesinoxan, gepirone and ipsapirone, 25 and pharmaceutically acceptable salts thereof.

This invention also relates to a method of treating a disorder or condition selected from the group consisting of panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias (e.g., specific animal phobias), social anxiety disorder, 30 social phobia, obsessive-compulsive disorder, and stress disorders including post-traumatic stress disorder and acute stress disorder in a mammal, preferably a human, comprising administering to a mammal in need of such treatment:



-8-

(a) a compound of the formula I, or a pharmaceutically acceptable salt thereof; and

(b) another compound that is an antidepressant or an antianxiety agent, or a pharmaceutically acceptable salt thereof;

5        wherein the amounts of the active agents "a" and "b" are chosen so as to render the combination therapeutically effective.

A more specific embodiment of this invention relates to any of the above methods wherein a therapeutic amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to  
10        a human for the treatment of any two or more comorbid disorders or conditions selected from those disorders and conditions the treatment of which is referred to in any of the above methods. This method is hereinafter also referred to as "the method for treating concomitant disorders"

Another more specific embodiment of this invention relates to the  
15        above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and concomitant panic disorder.

Another more specific embodiment of this invention relates to the  
20        above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and concomitant irritable bowel syndrome.

Another more specific embodiment of this invention relates to the  
25        above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and concomitant functional abdominal pain.

Another more specific embodiment of this invention relates to the  
30        above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and concomitant neuropathic pain.

Neuropathic pain is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system (International Association for

the Study of Pain). Nerve damage can be caused by trauma and disease and thus the term 'neuropathic pain' encompasses many disorders with diverse aetiologies. These include but are not limited to, diabetic neuropathy, post herpetic neuralgia, back pain, cervical radiculopathy, cancer neuropathy, chemotherapy-induced neuropathy, HIV neuropathy, Phantom limb pain, Carpal Tunnel Syndrome, chronic alcoholism, hypothyroidism, trigeminal neuralgia, uremia, trauma-induced neuropathy, or vitamin deficiencies. Neuropathic pain is pathological as it has no protective role. It is often present well after the original cause has dissipated, commonly lasting for years, significantly decreasing a patients quality of life (Woolf and Mannion 1999 Lancet 353: 1959-1964). The symptoms of neuropathic pain are difficult to treat, as they are often heterogeneous even between patients with the same disease (Woolf & Decosterd 1999 Pain Supp. 6: S141-S147; Woolf and Mannion 1999 Lancet 353: 1959-1964). They include spontaneous pain, which can be continuous, or paroxysmal and abnormal evoked pain, such as hyperalgesia (increased sensitivity to a noxious stimulus) and allodynia (sensitivity to a normally innocuous stimulus).

Another more specific embodiment of this invention relates to the above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and concomitant premenstrual dysphoric disorder or premenstrual syndrome.

Another more specific embodiment of this invention relates to the above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and concomitant major depressive disorder.

Another more specific embodiment of this invention relates to the above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and concomitant dysthymia.

-10-

Another more specific embodiment of this invention relates to the above method of treating concomitant disorders wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and a concomitant somatoform disorder selected from somatization disorder, conversion disorder, body dysmorphic disorder, hypochondriasis, somatoform pain disorder, undifferentiated somatoform disorder and somatoform disorder not otherwise specified. See Diagnostic and Statistical manual of Mental Disorders, Fourth Edition (DSM-IV), American Psychiatric Association, Washington, D.C., May 1194, pp. 435-436.

Another more specific embodiment of this invention relates to the above method of treating fibromyalgia wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia that is accompanied by one or more somatic symptoms selected from loss of appetite, sleep disturbances (*e.g.*, insomnia, interrupted sleep, early morning awakening, tired awakening), loss of libido, restlessness, fatigue, constipation, dyspepsia, heart palpitations, aches and pains (*e.g.*, headache, neck pain, back pain, limb pain, joint pain, abdominal pain), dizziness, nausea, heartburn, nervousness, tremors, burning and tingling sensations, morning stiffness, abdominal symptoms (*e.g.*, abdominal pain, abdominal distention, gurgling, diarrhea), and the symptoms associated with major depressive disorder (*e.g.*, sadness, tearfulness, loss of interest, feratfulness, helplessness, hopelessness, fatigue, low self esteem, obsessive ruminations, suicidal thoughts, impaired memory and concentration, loss of motivation, paralysis of will, reduced appetite, increased appetite).

The foregoing methods are also referred to herein, collectively, as the "inventive methods" or the "methods of this invention".

Preferred embodiments of the invention methods utilize a compound of Formula I that is 3-aminomethyl-5-methyl-hexanoic acid or, especially, (S)-3-(aminomethyl)-5-methylhexanoic acid, which is known generically as pregabalin.

-11-

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof. Examples of "alkyl" groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, iso- sec- and tert-butyl, pentyl, hexyl, heptyl, 3-ethylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.

The term "cycloalkyl", as used herein, refers to saturated monovalent carbocyclic groups containing from 3 to 8 carbons and are selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, unless otherwise stated.

The term "treating", as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or preventing one or more symptoms of such condition or disorder. The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.

Compounds of the formula I may contain chiral centers and therefore may exist in different enantiomeric and diastereomeric forms. Individual isomers can be obtained by known methods, such as optical resolution, optically selective reaction, or chromatographic separation in the preparation of the final product or its intermediate. This invention relates to all optical isomers and all stereoisomers of compounds of the formula I, both as racemic mixtures and as individual enantiomers and diastereoisomers of such compounds, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment defined above that contain or employ them, respectively. Individual enantiomers of the compounds of formula I may have advantages, as compared with the racemic mixtures of these compounds, in the treatment of various disorders or conditions.

In so far as the compounds of formula I of this invention are basic compounds, they are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often

-12-

desirable in practice to initially isolate the base compound from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert to the free base compound by treatment with an alkaline reagent and thereafter convert the free base to a pharmaceutically acceptable acid addition salt. The free base form of the compound may be regenerated by contacting the acid addition salt so formed with a base, and isolating the free base form of the compound in the conventional manner. The free base forms of compounds of the formula I prepared according to a process of the present invention differ from their respective acid addition salt forms somewhat in certain physical properties such as solubility, crystal structure, hygroscopicity, and the like, but otherwise such free base forms of the compounds and their respective acid addition salt forms are equivalent for purposes of the present invention.

Pharmaceutically acceptable acid addition salts of the basic compounds useful in the method of the present invention include nontoxic salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well nontoxic salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M. et al., "Pharmaceutical Salts," *J. of Pharma. Sci.*, 1977;66:1).

In so far as the compounds of formula I of this invention are acidic compounds, they are capable of forming a wide variety of different salts

-13-

with various inorganic and organic bases. A base addition salt of an acidic compound useful in the method of the present invention may be prepared by contacting the free acid form of the compound with a sufficient amount of a desired base to produce the salt in the conventional manner. A  
5 pharmaceutically acceptable base addition salt of an acidic compound useful in the above inventive methods be prepared by contacting the free acid form of the compound with a nontoxic metal cation such as an alkali or alkaline earth metal cation, or an amine, especially an organic amine. Examples of suitable metal cations include sodium cation ( $\text{Na}^+$ ),  
10 potassium cation ( $\text{K}^+$ ), magnesium cation ( $\text{Mg}^{2+}$ ), calcium cation ( $\text{Ca}^{2+}$ ), and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge, supra., 1977). The free acid forms of the  
15 compounds of formula I may be regenerated by contacting the base addition salt forms so formed with an acid, and isolating the free acid of the compound in the conventional manner. The free acid forms of the compounds useful in the above inventive methods differ from their respective salt forms somewhat in certain physical properties such as  
20 solubility, crystal structure, hygroscopicity, and the like, but otherwise they are equivalent to their respective free acids for purposes of the present invention.

Certain of the compounds useful in the methods of this invention can exist in unsolvated forms as well as solvated forms, including  
25 hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds useful in the methods of this invention can exist as two or more tautomeric forms. Tautomeric forms of the  
30 compounds may interchange, for example, via enolization/de-enolization and the like. A method of the present invention may utilize any tautomeric

-14-

form of an  $\alpha_2$  ligand, or a pharmaceutically acceptable salt thereof, as well as mixtures thereof.

The present invention also includes the above inventive methods that employ isotopically labelled compounds that are identical to those recited in Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as  $^2\text{H}$ ,  $^3\text{H}$ ,  $^{13}\text{C}$ ,  $^{11}\text{C}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{18}\text{O}$ ,  $^{17}\text{O}$ ,  $^{31}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{18}\text{F}$ , and  $^{36}\text{Cl}$ , respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labelled compounds of the present invention, for example those into which radioactive isotopes such as  $^3\text{H}$  and  $^{14}\text{C}$  are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, *i.e.*,  $^3\text{H}$ , and carbon-14, *i.e.*,  $^{14}\text{C}$ , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, *i.e.*,  $^2\text{H}$ , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.

The effectiveness of an orally administered drug is dependent upon the drug's efficient transport across the mucosal epithelium and its stability in entero-hepatic circulation. Drugs that are effective after parenteral administration but less effective orally, or whose plasma half-life is considered too short, may be chemically modified into a prodrug form.

A prodrug is a drug that has been chemically modified and may be biologically inactive at its site of action, but which may be degraded or modified by one or more enzymatic or other *in vivo* processes to the parent bioactive form.

-15-

This chemically modified drug, or prodrug, should have a different pharmacokinetic profile than the parent drug, enabling easier absorption across the mucosal epithelium, better salt formulation and/or solubility, improved systemic stability (for an increase in plasma half-life, for example). These chemical modifications may be, for example:

- 1) ester or amide derivatives which may be cleaved by, for example, esterases or lipases. For ester derivatives, the ester is derived from the carboxylic acid moiety of the drug molecule by known means. For amide derivatives, the amide may be derived from the carboxylic acid moiety or the amine moiety of the drug molecule by known means;
- 2) peptides which may be recognized by specific or nonspecific proteinases (A peptide may be coupled to the drug molecule via amide bond formation with the amine or carboxylic acid moiety of the drug molecule by known means);
- 3) derivatives that accumulate at a site of action through membrane selection of a prodrug form or modified prodrug form; or
- 4) any combination of 1 to 3.

Current research in animal experiments has shown that the oral absorption of certain drugs may be increased by the preparation of "soft" quaternary salts. The quaternary salt is termed a "soft" quaternary salt since, unlike normal quaternary salts, e.g.,  $R-N^+(CH_3)_3$ , it can release the active drug upon hydrolysis.

"Soft" quaternary salts have useful physical properties compared with the basic drug or its salts. Water solubility may be increased compared with other salts, such as the hydrochloride, but more important there may be an increased absorption of the drug from the intestine. Increased absorption is probably due to the fact that the "soft" quaternary salt has surfactant properties and is capable of forming micelles and unionized ion pairs with bile acids, etc., which are able to penetrate the



-16-

intestinal epithelium more effectively. The prodrug, after absorption, is rapidly hydrolyzed with release of the active parent drug.

5 The above inventive methods that employ prodrugs of compounds of formula I are included within the scope of this invention. Prodrugs and soft drugs are known in the art (Palomino E., *Drugs of the Future*, 1990;15(4):361-368). The last two citations are hereby incorporated by reference.

### Detailed Description Of The Invention

10

Alpha2delta ligands having the formula I, and the synthesis of such compounds, are described in US Patent 5,563,175 and US Patent 6,197,819, which are incorporated herein by reference in their entireties.

15 All that is required to practice the methods of this invention is to administer a compound of the formula I, or a pharmaceutically acceptable salt thereof, in an amount that is therapeutically effective to treat one or more of the disorders or conditions referred to above. Such therapeutically effective amount will generally be from about 1 to about 300 mg/kg body weight of the patient being treated. Typical doses will be from about 10 to about 5000 mg/day for an adult patient of normal weight. In a clinical setting, regulatory agencies such as, for example, the Food and Drug Administration ("FDA") in the U.S. may require a particular therapeutically effective amount.

25 In determining what constitutes an effective amount or a therapeutically effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, for treating one or more of the disorders or conditions referred to above according to the invention method, a number of factors will generally be considered by the medical practitioner or veterinarian in view of the mammal's age, sex, weight and general condition, as well as the type and extent of the disorder or condition being treated, and the use of other medications, if any, by the mammal receiving the treatment. As such, the administered dose may fall within the ranges or concentrations recited above, or may vary outside,

30

-17-

*i.e.*, either below or above, those ranges depending upon the requirements of the individual subject, the severity of the condition being treated, and the particular therapeutic formulation being employed. Determination of a proper dose for a particular situation is within the skill of the medical or veterinary arts. Generally, treatment may be initiated using smaller dosages of the active compound or compounds that are less than optimum for a particular subject. Thereafter, the dosage can be increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

The compounds of formula I and their pharmaceutically acceptable salts can be administered to mammals via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, buccal, topical or intranasal routes. Preferred routes of administration are oral and parenteral. Preferably, administration is in unit dosage form. A unit dosage form of a compound of formula I, or a pharmaceutically acceptable salt thereof, to be used in the methods of this invention may also comprise other compounds useful in the therapy of the disorder or condition for which the compound of formula I or pharmaceutically acceptable salt thereof is being administered or a disorder or condition that is secondary to the disorder condition for which the compound of formula I or pharmaceutically acceptable salt thereof is being administered.

Pharmaceutical compositions containing a compound of the formula I, or a pharmaceutically acceptable salt thereof, are produced by formulating the active compound in unit dosage form with a pharmaceutical carrier. Some examples of unit dosage forms are tablets, capsules, pills, powders, cachets, lozenges, creams, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses.

-18-

Some examples of suitable pharmaceutical carriers, including pharmaceutical diluents, are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and potato starch; cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol, glycerin; sorbitol; polyethylene glycol; water; agar; alginic acid; isotonic saline, and phosphate buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations.

The compositions to be employed in the methods of this invention can also contain other components such as coloring agents, flavoring agents, and/or preservatives. These materials, if present, are usually used in relatively small amounts. The compositions can, if desired, also contain other therapeutic agents commonly employed to treat the disorder or condition being treated.

The percentage of the active ingredients in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a concentration of at least 10% in a solid composition and at least 2% in a primary liquid composition. The most satisfactory compositions are those in which a much higher proportion of the active ingredient is present, for example, up to about 95%.

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. Powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier, providing a capsule in

-19-

which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The degree of binding of compounds of the formula I and their pharmaceutically acceptable salts to an  $\alpha 2\delta$  subunit of a calcium channel can be determined using the radioligand binding assay using [ $^3\text{H}$ ]gabapentin and the  $\alpha 2\delta$  subunit derived from porcine brain tissue, as described by N. S. Gee *et al.*, *J. Biol. Chem.*, 1996, 271:5879-5776.

The efficacy of pregabalin in treating fibromyalgia was demonstrated in the following in vivo experiment, which is summarized below.

-20-

SUMMARY:

Sprague-Dawley male rats given an intramuscular (IM) injection of 100  $\mu$ L sterile pyrogen-free saline, pH 4 in the gastrocnemius muscle on Days 1 and 5, develop chronic mechanical allodynia (static allodynia) approximately 1 week after the second injection. (Sluka KA, Kalra A, Moore SA. Intramuscular injections of acidic saline produce a bilateral long-lasting hyperalgesia. *Muscle & Nerve* 2001; 24:37-46.) Allodynia was measured by applying von Frey filaments of varying bending forces (0.41 to 29 g) to the plantar surface of the injected hind limb to determine paw withdrawal threshold (PWT). Evaluations were performed blinded, with the animals and treatments randomized. PWL, 1 to 2 weeks after the second acid saline injection was usually less than 5 g (reduced from 22 to 28 g prior to acid saline injection), representing tactile allodynia. Allodynia was sustained for 3 weeks. Rats injected with pH 7.2 saline showed no allodynia. After acid saline injection, there was no evidence for dynamic allodynia (measured by paw withdrawal to cotton swab stroking) or weight-bearing preference between the hind limbs. Treatment with pregabalin, 10 or 30 mg/kg by oral gavage (PO) 2 weeks after the last acid saline injection, reversed mechanical allodynia. Analgesic-like action of pregabalin was significantly greater than vehicle treatment at 2 to 3 hours after therapy. Morphine, 3 and 10 mg/kg subcutaneously (SC) reduced allodynia, while amitriptyline, 6 mg/kg SC did not alter allodynia. Fibromyalgia is classified by the American College of Rheumatology as chronic generalized musculoskeletal pain with allodynia to pressure over a majority of specified tender points. The results with acid saline-injected rats indicate that pregabalin reduces allodynia in a rat model with some similarities to the human disease of fibromyalgia.

METHODS:

*Acidic Saline-Induced Allodynia:* Male Sprague-Dawley rats (Harlan) approximately 350 g were housed in plastic isolators with organic cellulose bedding. Food and water were available ad libitum and animals were maintained on a 12 hr/12 hr light/dark cycle, with testing during the

-21-

light phase. On test days, rats were placed in a metal chamber on an elevated metal mesh floor and allowed to acclimate for at least 20 minutes. On Day 1, a baseline von Frey filament withdrawal threshold with the right hind paw was obtained. Later on Day 1, acidic saline, pH 4 (100  $\mu$ L) was injected in the right gastrocnemius muscle and a similar injection was made again in the same location on Day 5. On subsequent days, pain responses (von Frey filament withdrawal threshold, withdrawal in response to light stroking with a cotton swab, and changes in weight bearing between the 2 hind paws) were determined for both hind paws. Experimental drug treatments were evaluated for inhibitory effects on static allodynia and other pain endpoints. Rats with a paw withdrawal threshold (PWT) of 6 g or less on the day of drug testing (Days 14 to 18) were used. Rats were evaluated for PWTs at 1, 2, and 3 hours after receiving either drug or vehicle treatments.

#### MEASUREMENT OF PAIN-RELATED BEHAVIORAL RESPONSES

*Static Allodynia:* PWT was determined using von Frey filaments with varying bending forces (0.41, 0.69, 1.2, 2.0, 3.6, 5.5, 8.5, 15.1, and 28.8 g, Stoelting Corp, Wood Dale, IL). Pressure was applied to the plantar surface of a hind paw with a single slow application for up to 6 seconds to the plantar surface beginning with the 2.0-g filament. If no withdrawal was obtained, the next higher bending force filament was applied or, in the case of a withdrawal, the next lower force filament was applied. This continued until at least 6 responses were obtained, including at least 1 withdrawal. Withdrawal threshold at each time point (for each rat) then was determined using the Dixon , 'Up-Down' method. (Dixon WJ. Efficient analysis of experimental observations. Ann Rev Pharmacol Toxicol 1980; 20:441-62.) If no withdrawal was obtained with the 28.8 g filament, a withdrawal threshold of 29 g was assigned.

*Dynamic Allodynia:* The plantar surfaces of injected and contralateral hind paws were gently stroked with a cotton swab, applied

-22-

from underneath the wire mesh for up to 15 seconds. Withdrawal time (mean of triplicate values) is reported, with a maximum value of 15 seconds recorded if no withdrawal was observed.

5           *Spontaneous Pain:* The rat was placed in a compact clear acrylic plastic box with an elevated platform for the forepaws and a square cutaway in the base for the hind paws. The box was designed to allow contact of the hind paws to each of 2 force transducer plates of an incapitance tester (Linton Instruments, Norfolk, England), that measured  
10           the force applied by each of the hind paws to the floor of the chamber. The weight (in grams) applied to each paw was averaged by the device over a 4-second period and recorded. Reported values are the mean of triplicate readings of the difference in weight applied to the 2 hind paws (contralateral minus injected hind paw).

15

## RESULTS

*Characterization of the Model:* Two repeated intramuscular injections of acidic saline caused a sustained decrease in the von Frey withdrawal threshold to the planter surface of the previously injected hind  
20           limb. These results were similar to those published previously. (Sluka KA, Kalra A, Moore SA. Intramuscular injections of acidic saline produce a bilateral long-lasting hyperalgesia. Muscle & Nerve 2001; 24:37-46.) However, in contrast to the previously published findings, little or no change in withdrawal threshold was observed in the hind limb contralateral  
25           to acidic saline injection except at the latest time point tested (Table 1). No changes were observed in withdrawal in response to the cotton swab stimulus or weight bearing endpoints in either hind paw. A representative experiment is shown in Table 2.

30

*Pharmacological Evaluations of Pregabalin in the Acidic Saline Induced Allodynia Model:* Rats injected with acidic saline on Days 1 and 5 were evaluated for changes in pain responses on alternate days, beginning at Day 14, following the last acidic saline injection. On a given

-23-

day, only rats showing allodynia (withdrawal in response to von Frey filaments of 6 g or less) and naïve to previous drug treatments were used to evaluate test compounds. Pregabalin or vehicle (water) was given PO, 30 minutes after baseline paw withdrawal readings. Rats were evaluated at 1, 2, and 3 hours after drug or vehicle treatment. Pregabalin at either 10 or 30 mg/kg PO inhibited static allodynia (measured by von Frey filaments) when tested either 2 or 3 hours after drug treatment (Table 3). Pregabalin treatment at 3 mg/kg PO was without effect on allodynia.

Morphine, 10 mg/kg SC, given 30 minutes after baseline measurements, inhibited static allodynia at 1 and 2 hours after treatment (Table 4). Similar treatment with morphine, 3 mg/kg, increased PWTs, but only at 1 hour (not 2 or 3 hours) after treatment. Amitriptyline, 6 mg/kg SC, did not alter PWTs at 1, 2, or 3 hours posttreatment (Table 5).

Prior repeated injection of pH 4 saline in the gastrocnemius induced mechanical allodynia (measured with von Frey filaments) of several weeks duration to the ipsilateral plantar surface of the hind paw. The same rats did not have dynamic allodynia of the hind paw (in response to cotton swab stroking) or spontaneous pain behavior (a weight bearing preference between the hind paws). Pregabalin 10 and 30 mg/kg PO reduced static allodynia produced by prior acidic saline injections. Morphine 3 and 10 mg/kg SC, reduced static allodynia from prior acidic saline injections. Amitriptyline, 6 mg/kg PO was without inhibitory effects on allodynia. These results agree with previous published results for morphine. (Sluka, KA, Rohlwing JJ, Bussey RA, Eikenberry SA, Wilken JM. *J Pharmacol. Exp. Ther.* 2002, 302:1146-50). Although amitriptyline was without effect in this study, it is often prescribed for fibromyalgia pain, and clinical studies has shown it to be effective. 5,6 It is possible that amitriptyline would be effective in this animal model (with allodynia from repeated acidic saline injections) if it were tested after repeated dosing for several days. This possibility remains to be tested. Higher dosages of amitriptyline were not studied because tachycardia was observed at the 6 mg/kg PO dose and a 10 mg/kg PO dose was lethal in a fraction of rats that were injected.



-24-

Static allodynia in the rat hind paw produced by prior repeated injections of acidic saline into the gastrocnemius muscle may provide a method to evaluate novel agents for treating chronic musculoskeletal pain. This animal model may be of use to evaluate experimental analgesic compounds for the treatment of chronic allodynia in syndromes such as fibromyalgia.

Table 1. Rat Paw Withdrawal Threshold (PWT) of the Plantar Hind Paw Surface of the Left (Ipsilateral) and Right (Contralateral) Side, Before and After 2 Injections of 100  $\mu$ L of Acidic Saline, pH 4.2 on the Left Gastrocnemius Muscle

Hind Limb	Day 1 Before Injection	Day 5 Post- Initial Injection	Day 12 Post- Initial Injection	Day 16 Post- Initial Injection	Day 26 Post- Initial Injection
Ipsilateral PWT	27.47	28.84	13.19 <sup>a,b</sup>	7.86 <sup>a,b</sup>	10.93 <sup>b</sup>
SEM	1.11	0.00	3.64	2.07	2.80
Contralateral PWT	28.84	25.64	28.84	28.84	17.58 <sup>b</sup>
SEM	0.00	2.48	0.00	0.00	3.61

N = 9, Data are mean values in grams.

<sup>a</sup> p <0.05, injected versus contralateral hindlimb, one-way ANOVA on ranks with Tukey test.

<sup>b</sup> p <0.05 versus baseline on Day 1, before first injection, one-way ANOVA on ranks with Tukey test.

Table 2. Paw Withdrawal Threshold (Ipsilateral), Paw Withdrawal Latency (Ipsilateral), and Weight Bearing Measurements at Different Times Before (Day 1) and After (Days 5 and 8) 2 Acid Saline Injections to the Gastrocnemius Muscle

	Day 1 Before Injection	Day 5 Postinitial Injection	Day 18 Post Initial Injection
<b>Paw Withdrawal Threshold to von Frey Filaments (g)</b>			
pH 7.4	25.59	20.15	23.50
SEM	2.28	3.65	3.94
pH 4.2	27.47	12.42a	9.89a
SEM	1.11	3.175	2.48
<b>Paw Withdrawal Latency to Cotton Swab Stroking (sec)</b>			
pH 7.4	9.39	10.83	9.11
SEM	0.65	0.34	0.93
pH 4.2	9.17	6.33	9.78
SEM	0.40	1.34	1.96
<b>Weight Bearing: Contralateral Force Minus Ipsilateral Force (g)</b>			
pH 7.4	-3.0	-2.0	-10.0
SEM	5.0	6.0	4.0
pH 4.2	7.0	5.0	-13.0
SEM	5.0	5.0	14.0

<sup>a</sup> p <0.05 versus Day 1 by one-way ANOVA on ranks and Tukey test, n = 6/group. Data are means values.

-25-

Table 3. Rat Paw Withdrawal Threshold Before and After Treatment With Pregabalin PO Following Prior Repeated Acid Saline Injections to the Gastrocnemius Muscle<sup>a</sup>

	Day 1	Baseline	1 hr Post Rx	2 hr Post Rx	3 hr Post Rx
Vehicle	27.75	3.52	9.87	7.07	12.13
SE	1.09	0.35	4.05	2.24	5.04
Pregabalin, 3 mg/kg PO	27.37	5.32	7.92	4.53	6.07
SEM	1.08	0.51	2.99	1.16	1.13
N=6/group					
Vehicle	18.65	4.72	11.70	4.17	3.74
SEM	2.50	0.90	5.78	0.70	1.42
Pregabalin, 10 mg/kg PO	24.90	3.55	2.28	28.84 <sup>b</sup>	22.23 <sup>b</sup>
SEM	3.94	0.14	0.68	0.00	6.62
N=4/group					
Vehicle	28.84	4.57	12.95	3.61	5.05
SEM	0.00	0.73	4.47	0.62	2.19
Pregabalin, 30 mg/kg PO	26.07	4.74	18.15	25.11 <sup>b</sup>	23.74 <sup>b</sup>
SEM	1.81	0.75	4.20	2.65	4.67

N = 6/group

<sup>a</sup> Paw withdrawal threshold measured by von Frey filaments, all measurements in grams; all drug treatments given 30 minutes after baseline measurements.

<sup>b</sup> Significantly different from vehicle group ( $p < 0.05$ , 1-way ANOVA on ranks then Tukey Test, all pairwise comparison procedures). Data are mean values.

-26-

Table 4. Rat Static Allodynia Before and After Treatment With Morphine SC <sup>a</sup>

	Day 1	Baseline	1 hr Post	2 hr Post Rx	3 hr Post Rx
Vehicle	28.24	4.11	4.07	9.99	9.74
SEM (n = 11)	0.60	0.39	0.65	3.32	2.70
Morphine, 3 mg/kg SC	24.27	2.89	20.52 <sup>b</sup>	9.93	7.09
SEM (n = 10)	1.54	0.41	3.33	3.23	2.25
Vehicle	28.84	3.33	4.56	5.47	4.67
SEM (n = 6)	0.00	0.41	0.91	1.98	0.75
Morphine, 10 mg/kg SC	26.63	3.09	28.840 <sup>b</sup>	22.05 <sup>b</sup>	16.91
SEM (n = 6)	2.21	0.60	0.00	4.32	4.58

<sup>a</sup> Paw withdrawal threshold measured by von Frey filaments, all measurements in grams; all drug treatments given 30 minutes after baseline measurements.

<sup>b</sup> p < 0.05 versus baseline measurement, 1-way ANOVA on ranks, and Tukey test. Data are mean values.

Table 5. Rat Static Allodynia Before and After Treatment With Amitriptyline, SC <sup>a</sup>

	Day 1	Baseline	1 hr Post Rx	2 hr Post Rx	3 hr Post Rx
Vehicle	28.84	3.06	8.64	8.64	11.50
SEM	0.00	0.28	4.27	2.02	5.52
Amitriptyline, 6 mg/kg	24.44	2.36	12.01	7.38	7.20
SEM	2.21	0.40	4.55	2.74	4.03

N = 6/group. There was no significant difference between groups (1 way ANOVA on ranks and Tukey test).

<sup>a</sup> Drug is given 30 minutes after the baseline measurement.

- 5 A clinical study of the effect of pregabalin on human patients with fibromyalgia was also conducted. This study was conducted to assess the efficacy of pregabalin (150, 300, and 450 mg/day) compared with placebo for the relief of pain and improvement in functional status in patients with fibromyalgia. Patients who participated in the study must
- 10 have met the American College of Rheumatology criteria for fibromyalgia (widespread pain present for at least 3 months, and pain in at least 11 of 18 tender point sites).

### METHODOLOGY

- 15 Following a 1-week baseline phase, qualified patients were randomized to receive either 150, 300, or 450 mg/day pregabalin or

-27-

placebo according to an 8-week, double-blind, multicenter study design. The intent-to-treat (ITT) population comprised a total of 529 patients: 132 patients received 450 mg/day, 134 received 300 mg/day, 132 received 150 mg/day pregabalin, and 131 received placebo. The first phase of the 8-week double-blind phase consisted of a 1-week titration phase. Patients randomized to the placebo, 150 and 300 mg/day pregabalin treatment groups started out at their fixed dose at Day 1. Patients randomized to 450 mg/day pregabalin treatment group started at 300 mg/day and titrated to the target dose of 450 mg/day on Day 4, and remained at the fixed dose for the remainder of the double-blind period. Following Week 8 of the double-blind phase, patients had the option of entering an open-label follow-on study (Protocol 1008-033).

#### CRITERIA FOR EVALUATION

The primary efficacy measurements were derived from the daily, self-assessed pain score from the patient diary. Secondary measures were derived from the SF-MPQ, Manual Tender Point Survey, quality of sleep score from the daily diary, Multidimensional Assessment of Fatigue (MAF), Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change (PGIC), the SF-36 Health Survey (SF-36), Hospital Anxiety and Depression Scale (HADS), and Medical Outcomes Study (MOS) Sleep Scale.

#### RESULTS

All analyses were performed on the ITT population, defined as all randomized patients who received at least one dose of study medication. The primary efficacy measure, endpoint mean pain score, was significantly better for 450 mg/day pregabalin compared to placebo. A significant difference from placebo was seen in mean pain scores at Week 1 for the 450 mg/day pregabalin group and continued through Week 7. Similar results were seen for the 450 mg/day pregabalin group in most other secondary parameters including: Mean quality of sleep at each week and at endpoint, SF-MPQ sensory, affective, and total scores at endpoint

-28-

and VAS at endpoint, CGIC, PGIC, and the MAF Global Fatigue Index. A significant difference favoring 450 mg/day pregabalin compared to placebo was seen in the Social Functioning, Bodily Pain, Vitality, and General Health Perception domains of the SF-36 Health Survey.

5 Responder status (defined as the number of patients reporting at least 50% reduction in pain at endpoint compared to baseline) was significantly better for patients in the 450 mg/day pregabalin group compared to placebo (28.9% and 13.2%, respectively;  $p=0.003$ ). Patients in the 300 and 150 mg/day pregabalin groups were not significantly different from

10 placebo for the primary efficacy parameter. Both 300 and 150 mg/day pregabalin showed significant differences in many of the secondary parameters compared to placebo.

### CONCLUSIONS

15 Pregabalin was found to be effective at a dose of 450 mg/day in reducing pain associated with fibromyalgia. There was no significant effect on pain at the 150- and 300-mg/day doses. Both the 300 and 450 mg/day pregabalin treatment arms were superior to placebo on improvement in fatigue, clinician and patient global assessments of change, and


20 improvement of sleep quality.

-29-

## CLAIMS

What is claimed is:

1. A method of treating fibromyalgia in a mammal comprising  
 5 administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula I




or a pharmaceutically acceptable salt thereof, wherein:

- $\text{R}_1$  is a straight or branched unsubstituted alkyl of from 1 to 5 carbon  
 10 atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;  
 $\text{R}_2$  is hydrogen or methyl; and  
 $\text{R}_3$  is hydrogen, methyl, or carboxyl.

- 15 2. A method of treating a disorder or condition selected from the group consisting of sleep disorders such as insomnia (e.g., primary insomnia including psychophysiological and idiopathic insomnia, secondary insomnia including insomnia secondary to restless legs syndrome, Parkinson's disease or another chronic disorder, and transient insomnia),  
 20 somnambulism, sleep deprivation, REM sleep disorders, sleep apnea, hypersomnia, parasomnias, sleep-wake cycle disorders, jet lag, narcolepsy, sleep disorders associated with shift work or irregular work schedules, deficient sleep quality due to a decrease in slow wave sleep caused by medications or other sources, and other sleep disorders in a  
 25 mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula I

-30-




or a pharmaceutically acceptable salt thereof, wherein:

R<sub>1</sub> is a straight or branched unsubstituted alkyl of from 1 to 6 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

R<sub>2</sub> is hydrogen or methyl; and

R<sub>3</sub> is hydrogen, methyl, or carboxyl.

3. A method of increasing slow wave sleep in a human subject comprising administering to a human subject in need of such treatment an amount of a compound of the formula I



or a pharmaceutically acceptable salt thereof, wherein:

R<sub>1</sub> is a straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;


R<sub>2</sub> is hydrogen or methyl; and

R<sub>3</sub> is hydrogen, methyl, or carboxyl;

that is effective in increasing slow wave sleep.

4. A method of increasing secretion of a human growth hormone in a human subject comprising administering to a human subject in need of such treatment an amount of a compound of the formula I

-31-



or a pharmaceutically acceptable salt thereof, wherein:


$\text{R}_1$  is a straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

$\text{R}_2$  is hydrogen or methyl; and

$\text{R}_3$  is hydrogen, methyl, or carboxyl;

that is effective in increasing secretion of a human growth hormone.

5. A method of treating irritable bowel syndrome in a mammal; preferably a human, comprising administering to a human subject in need of such treatment a therapeutically effective amount of a compound of the formula I



or a pharmaceutically acceptable salt thereof, wherein:

$\text{R}_1$  is a straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

$\text{R}_2$  is hydrogen or methyl; and


$\text{R}_3$  is hydrogen, methyl, or carboxyl.

6. A method of treating a disorder or condition selected from the group consisting of panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, social



-32-

anxiety disorder, social phobia, obsessive-compulsive disorder, and stress disorders including post-traumatic stress disorder and acute stress disorder in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula I



or a pharmaceutically acceptable salt thereof, wherein:


$\text{R}_1$  is a straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

$\text{R}_2$  is hydrogen or methyl; and

$\text{R}_3$  is hydrogen, methyl, or carboxyl.

7. A method of treating a disorder or condition selected from the group consisting of panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, social anxiety disorder, social phobia, obsessive-compulsive disorder, and stress disorders including post-traumatic stress disorder and acute stress disorder in a mammal, comprising administering to a mammal in need of such treatment:

(a) a compound of the formula I



or a pharmaceutically acceptable salt thereof, wherein:

-33-

R<sub>1</sub> is a straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

R<sub>2</sub> is hydrogen or methyl; and

5 R<sub>3</sub> is hydrogen, methyl, or carboxyl. compound of the formula I, or a pharmaceutically acceptable salt thereof; and

(b) another compound that is an antidepressant or an antianxiety agent, or a pharmaceutically acceptable salt thereof;

10 wherein the amounts of the active agents "a" and "b" are chosen so as to render the combination therapeutically effective.

8. A method according to claim 7, wherein the disorder or condition being treated is post traumatic stress disorder, social phobia or social anxiety disorder.


15

9. A method of treating two or more disorders or conditions, each of which is independently selected from the group consisting of irritable bowel syndrome, fibromyalgia, neuropathic pain, sleep disorders such as insomnia (e.g., primary insomnia including psychophysiological and idiopathic insomnia, secondary insomnia including insomnia secondary to restless legs syndrome, Parkinson's disease or another chronic disorder, and transient insomnia), somnambulism, sleep deprivation, REM sleep disorders, sleep apnea, hypersomnia, parasomnias, sleep-wake cycle disorders, jet lag, narcolepsy, sleep disorders associated with shift work or irregular work schedules, deficient sleep quality due to a decrease in slow wave sleep caused by medications or other sources, other sleep disorders, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, social anxiety disorder, social phobia, obsessive-compulsive disorder, and stress disorders including post-traumatic stress disorder and acute stress disorder in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula I

20

25

30



or a pharmaceutically acceptable salt thereof, wherein:

R<sub>1</sub> is a straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms;

R<sub>2</sub> is hydrogen or methyl; and

R<sub>3</sub> is hydrogen, methyl, or carboxyl.

10. A method according to claim 1 wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and a concomitant disorder or condition selected from panic disorder, irritable bowel syndrome, functional abdominal pain, neuropathic pain, major depressive disorder and dysthymia.

11. A method according to claim 1 wherein a compound of the formula I, or a pharmaceutically acceptable salt thereof, is administered to a human for the treatment of fibromyalgia and a concomitant somatoform disorder selected from somatization disorder, conversion disorder, body dysmorphic disorder, hypochondriasis, somatoform pain disorder, undifferentiated somatoform disorder and somatoform disorder not otherwise specified.

12. A method of increasing slow wave sleep in a human subject being treated with an active pharmaceutical agent that decreases slow wave sleep comprising administering to such human subject a therapeutically effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.

-35-

13. A method of increasing slow wave sleep in a human subject comprising administering to a human subject in need of such treatment:

5 (a) a compound of the formula I or a pharmaceutically acceptable salt thereof; and

(b) a human growth hormone or human growth hormone secretagogue, or a pharmaceutically acceptable salt thereof;

10 wherein the amounts of the active agents "a" and "b" are chosen so as to render the combination effective in increasing slow wave sleep.

14. A method of increasing slow wave sleep in a human subject being treated with an active pharmaceutical agent that decreases slow wave sleep comprising administering to a human subject in need of such treatment:

15 (a) a compound of the formula I or a pharmaceutically acceptable salt thereof; and

(b) a human growth hormone or human growth hormone secretagogue, or a pharmaceutically acceptable salt thereof;

20 wherein the amounts of the active agents "a" and "b" are chosen so as to render the combination effective in increasing slow wave sleep.

15. A method according to any of claims 1 – 14 wherein the compound of formula I that is administered is pregabalin.

25

## INTERNATIONAL SEARCH REPORT

Intern Application No  
PCT/IB 03/05684

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K31/197 A61P1/00 A61P25/18 A61P29/00 A61P43/00  
 A61P5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, MEDLINE, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AMERINGEN VAN M ET AL: "DRUGS IN DEVELOPMENT FOR SOCIAL ANXIETY DISORDER: MORE TO SOCIAL ANXIETY THAN MEETS THE SSRI" EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 9, no. 10, 2000, pages 2215-2231, XP009027468 ISSN: 1354-3784 the whole document	6,7,15
X	GUYMER E K ET AL: "AN APPROACH TO MANAGING FIBROMYALGIA" MEDICINE TODAY, XX, JP, vol. 3, no. 12, 1 December 2002 (2002-12-01), pages 58-59, XP009027465 the whole document	1,9-11, 15
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

22 March 2004

Date of mailing of the international search report

08/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Trifilieff-Riolo, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/05684

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HIDALGO ET AL.: "SOCIAL ANXIETY DISORDER IN REVIEW" INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, vol. 4, no. 3, 2001, pages 279-298, XP009027466 page 290 -page 291	6,7,15
X	FELTNER ET AL.: "A PLACEBO-CONTROLLED DOUBLE-BLING STUDY OF PREGABALIN TREATMENT OF SOCIAL PHOBIA" EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 10, no. 3, 2000, page S345 XP009027464 abstract	6,7,15
X	VLASOV N.A.: "EFFECT OF DERIVATIVES OF GABA ON SLEEP DISTURBANCES IN NEUROSIS" BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 85, no. 2, 1978, pages 169-171, XP009027469	2,3,9,12
Y	the whole document	13,14
X	DAVIDSON J.R.T.: "ADVANCES AND EMERGING TREATMENTS IN SOCIAL PHOBIA" JOURNAL OF CLINICAL PSYCHIATRY, vol. 62, no. 1, 2001, page 4 XP009027467 the whole document	6,7,15
X	MELTZER ET AL.: "PREGABALIN ENHANCES NON-RAPID EYE MOVEMENT SLEEP AND EEG SLOW-WAVE ACTIVITY IN RATS" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, page 2245 XP001180051	2,3,9,15
Y	abstract	13,14
X	DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1986 DANILIN V P ET AL: "'Effect of fenibut on the nocturnal sleep of patients with the alcoholic abstinence syndrome!" Database accession no. NLM3705831 XP002274082 abstract & ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S.S. KORSAKOVA (MOSCOW, RUSSIA: 1952) USSR 1986, vol. 86, no. 2, 1986, pages 251-254, ISSN: 0044-4588	2

-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/05684

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 31020 A (WARNER LAMBERT CO ;WUSTROW DAVID JUERGEN (US); BELLIOTTI THOMAS RI) 2 June 2000 (2000-06-02) claim 12	6,7
X	WO 00 02546 A (SEGAL CATHERINE A ;WARNER LAMBERT CO (US); MAGNUS MILLER LESLIE (U) 20 January 2000 (2000-01-20) claims 6-9	2,15
X	EP 0 974 351 A (JOUVEINAL) 26 January 2000 (2000-01-26) page 3, line 1 - line 23	5,15
X	US 6 359 005 B1 (PANDE ATUL CHANDRA) 19 March 2002 (2002-03-19) column 4; table 1	2,15
X	WO 98 03167 A (SINGH LAKHBIR ;WARNER LAMBERT CO (US)) 29 January 1998 (1998-01-29) page 1, line 23 page 2, line 1 - line 18	1,9-11
X	WO 98 17627 A (BRYANS JUSTIN STEPHEN ;HORWELL DAVID CHRISTOPHER (GB); KNEEN CLARE) 30 April 1998 (1998-04-30) page 1, line 14 -page 3	6,9
X	WO 00 67742 A (MAGISTRO PHILIP JOHN JR ;WARNER LAMBERT CO (US)) 16 November 2000 (2000-11-16) claims 27,28	5
X	WO 99 08670 A (BUENO LIONEL ;CHOVET MARIA (FR); DIOP LAURENT (FR); LITTLE HILARY) 25 February 1999 (1999-02-25) page 3, line 10 - line 26 page 2, line 5	5
X	US 6 372 792 B1 (CHOUINARD GUY) 16 April 2002 (2002-04-16) claim 3.	2,15
X	WO 00 76958 A (BRYANS JUSTIN STEPHEN ;SCHELKUN ROBERT MICHAEL (US); WARNER LAMBER) 21 December 2000 (2000-12-21) claims 5,6,21,24,25	5,6,9
X	SELAKE I.: "PREGABALIN" CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 2, no. 6, 2001, pages 828-834, XP009020712 the whole document	2,6-9,15

-/-

## INTERNATIONAL SEARCH REPORT

 Inter  
 ial Application No  
 PCT/IB 03/05684

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 1997 (1997-11) BELOZERTSEVA I V ET AL: "'A pharmaco-ethological study of the GABA-ergic mechanisms regulating the depression-like behavior of mice!" Database accession no. NLM9472168 XP002274083 abstract & ZHURNAL VYSSHEI NERVNOI DEIATELNOSTI IMENI I P PAVLOVA. RUSSIA 1997 NOV-DEC, vol. 47, no. 6, November 1997 (1997-11), pages 1024-1031, ISSN: 0044-4677	6,7
Y	DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2001 MARSHALL L ET AL: "Changes in immune cell counts and interleukin (IL)-1'beta! production in humans after a somnogenically active growth hormone-releasing hormone (GHRH) administration" Database accession no. EMB-2001408928 XP002273952 abstract & BRAIN, BEHAVIOR, AND IMMUNITY 2001 UNITED STATES, vol. 15, no. 3, 2001, pages 227-234, ISSN: 0889-1591	13,14
X,P	BRILEY ET AL.: "FIBROMYALGIA SYNDROME: AN OVERVIEW OF POTENTIAL DRUG TARGETS" IDRUGS, vol. 6, 2003, pages 668-673, XP002274081 page 670, left-hand column	1,9-11, 15
X,P	WO 02 100347 A (XENOPORT INC) 19 December 2002 (2002-12-19) claims 28,103,105	2,6,9
X,P	WO 03 061656 A (SCHLAGHECK THOMAS G ;GALER BRADLEY S (US); ENDO PHARMACEUTICALS IN) 31 July 2003 (2003-07-31) claims 5,17,18	6
X	KUBOTA ET AL.: "PREGABALIN ENHANCES NONRAPID EYE MOVEMENT SLEEP" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 299, 2001, pages 1095-1105, XP002274345	2,3,12
Y	the whole document	13,14



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 03/05684

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 03/05684

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0031020	A	02-06-2000	AU 1602100 A WO 0031020 A1 US 6627771 B1	13-06-2000 02-06-2000 30-09-2003
WO 0002546	A	20-01-2000	AU 765038 B2 AU 4967399 A BR 9911887 A CA 2333024 A1 EP 1094803 A2 ID 27191 A JP 2002520277 T NO 20010117 A NZ 509231 A PL 345338 A1 WO 0002546 A2 US 6306910 B1 US 2002004528 A1 ZA 200007174 A	04-09-2003 01-02-2000 27-03-2001 20-01-2000 02-05-2001 08-03-2001 09-07-2002 08-01-2001 29-08-2003 17-12-2001 20-01-2000 23-10-2001 10-01-2002 04-03-2002
EP 0974351	A	26-01-2000	EP 0974351 A2	26-01-2000
US 6359005	B1	19-03-2002	AU 762599 B2 AU 5493099 A CA 2344407 A1 EP 1121114 A1 HU 0103842 A2 JP 2002527474 T NZ 510920 A WO 0023067 A1 ZA 200102561 A	26-06-2003 08-05-2000 27-04-2000 08-08-2001 28-02-2002 27-08-2002 28-08-2002 27-04-2000 30-09-2002
WO 9803167	A	29-01-1998	AT 241351 T AU 714980 B2 AU 3602497 A BR 9710536 A CA 2255652 A1 CN 1223574 A , B DE 69722426 D1 DK 934061 T3 EP 0934061 A1 HK 1021134 A1 HR 970387 A1 HU 9904361 A2 IL 126999 A JP 2000515149 T NO 990279 A NZ 332762 A PL 331325 A1 PT 934061 T SI 934061 T1 US 6001876 A WO 9803167 A1 ZA 9706562 A	15-06-2003 13-01-2000 10-02-1998 17-08-1999 29-01-1998 21-07-1999 03-07-2003 22-09-2003 11-08-1999 18-07-2003 31-10-1998 28-05-2000 10-03-2002 14-11-2000 22-01-1999 29-09-2000 05-07-1999 31-10-2003 31-10-2003 14-12-1999 29-01-1998 03-02-1998
WO 9817627	A	30-04-1998	AU 733896 B2 AU 4669797 A BR 9712651 A CA 2263663 A1	31-05-2001 15-05-1998 26-10-1999 30-04-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 03/05684

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9817627	A		EP 0937032 A1 HR 970560 A1 JP 2002514187 T NZ 334898 A WO 9817627 A1 US 6153650 A ZA 9709457 A	25-08-1999 31-08-1998 14-05-2002 29-09-2000 30-04-1998 28-11-2000 12-05-1998
WO 0067742	A	16-11-2000	AU 3735000 A WO 0067742 A2	21-11-2000 16-11-2000
WO 9908670	A	25-02-1999	AU 8668598 A AU 9293098 A BR 9812133 A CA 2297163 C EP 1009399 A1 HU 0004551 A2 JP 2001515033 T NO 20000786 A NZ 502729 A PL 338705 A1 WO 9908670 A1 WO 9908671 A1 US 6127418 A US 6242488 B1 US 2001014698 A1 ZA 9807493 A	08-03-1999 08-03-1999 18-07-2000 20-11-2001 21-06-2000 28-05-2001 18-09-2001 17-02-2000 25-10-2002 20-11-2000 25-02-1999 25-02-1999 03-10-2000 05-06-2001 16-08-2001 07-07-1999
US 6372792	B1	16-04-2002	NONE	
WO 0076958	A	21-12-2000	AU 5311900 A BG 106292 A BR 0011727 A CA 2374755 A1 CN 1355784 T CZ 20014285 A3 EE 200100672 A EP 1192125 A2 HR 20020025 A2 HU 0201601 A2 JP 2003502308 T NO 20015949 A PL 352431 A1 SK 17642001 A3 TR 200103587 T2 WO 0076958 A2 US 2003181523 A1 ZA 200109711 A	02-01-2001 31-05-2002 05-03-2002 21-12-2000 26-06-2002 17-07-2002 17-02-2003 03-04-2002 31-12-2003 28-10-2002 21-01-2003 05-12-2001 25-08-2003 08-10-2002 22-04-2002 21-12-2000 25-09-2003 20-03-2003
WO 02100347	A	19-12-2002	CA 2449673 A1 CA 2449729 A1 WO 02100347 A2 WO 02100392 A1 US 2003083382 A1 US 2003176398 A1 US 2004006132 A1 US 2004014940 A1	19-12-2002 19-12-2002 19-12-2002 19-12-2002 01-05-2003 18-09-2003 08-01-2004 22-01-2004

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 03/05684

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03061656	A	31-07-2003	WO 03061656 A1	31-07-2003

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number  
**WO 2004/054565 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/197**,  
A61P 1/00; 25/18, 29/00, 43/00, 5/00

(74) Agents: LUMB, J., Trevor et al.; c/o David J. Wood,  
Pfizer Global Research and Development, UK Patent  
Department, Ramsgate Road, Sandwich, Kent CT13 9NJ  
(GB).

(21) International Application Number:  
PCT/IB2003/005684

(22) International Filing Date: 3 December 2003 (03.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data:  
60/433,491 13 December 2002 (13.12.2002) US  
60/483,482 27 June 2003 (27.06.2003) US

(84) Designated States (*regional*): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**WARNER-LAMBERT COMPANY LLC** [US/US];  
201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **TAYLOR, Charles,  
Price, Jr.** [US/US]; Pfizer Global Research and Devel-  
opment, Ann Arbor Laboratories, 2800 Plymouth Road,  
Ann Arbor, MI 48105 (US). **THORPE, Andrew, John**  
[GB/US]; Pfizer Global Research and Development, Ann  
Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI  
48105 (US). **WANG, Fong** [US/US]; Pfizer Global Re-  
search and Development, Ann Arbor Laboratories, 2800  
Plymouth Road, Ann Arbor, MI 48105 (US). **WUSTROW,  
David, Juergen** [US/US]; Pfizer Global Research and De-  
velopment, Ann Arbor Laboratories, 2800 Plymouth Road,  
Ann Arbor, MI 48105 (US).

Published:

— with international search report

(48) Date of publication of this corrected version:

10 September 2004

(15) Information about Correction:

see PCT Gazette No. 37/2004 of 10 September 2004, Sec-  
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: PREGABALIN AND DERIVATES THEREOF FOR THE TREATMENT OF FIBROMYALGIA AND OTHER RE-  
LATED DISORDERS

(57) Abstract: The invention relates to a method of treating fibromyalgia and other disorders in a mammal by administering a  
compound compound of Formula R<sub>1</sub> is straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl,  
or unsubstituted cycloalkyl of from 3 to 6 carbon atoms; R<sub>2</sub> is hydrogen or methyl; and R<sub>3</sub> is hydrogen, methyl, or carboxyl, or a  
pharmaceutically acceptable salt thereof.

WO 2004/054565 A1